Anti-CD19 CAR T-Cell Therapy(Fondazione Policlinico Universitario Agostino Gemelli Irccs)

N/A

Report date: 2024/11/13 20:00:43

Base Information

Drug NameAnti-CD19 CAR T-Cell Therapy(Fondazione Policlinico Universitario Agostino Gemelli Irccs)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Leukocyte-derivedCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector +[4] 
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFondazione Policlinico Universitario Agostino Gemelli Irccs
China Registration ClassN/A

Develop Information

Active CompaniesFondazione Policlinico Universitario Agostino Gemelli Irccs
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A